EAA 2026 for Pharmaceutical Companies: Making Patient Information Leaflets Accessible
Pharmaceutical companies distributing patient information leaflets (PILs), summary of product characteristics (SmPCs), and other documents to EU consumers must comply with the European Accessibility Act (EAA). Enforcement started June 28, 2026.
The pharmaceutical sector faces a unique challenge: regulatory formats are specified by the EMA and national competent authorities, creating potential conflict between mandatory document structure and accessibility requirements. This guide explains the requirements and the most practical compliance path.
Which pharmaceutical documents fall under EAA?
EAA Article 2 covers services and products offered to consumers in the EU. In the pharmaceutical sector, digital documents distributed to patients and healthcare professionals are in scope:
- Patient Information Leaflets (PILs) — the patient-facing document inside every medicinal product package; increasingly distributed digitally via QR code or product website
- Summary of Product Characteristics (SmPCs) — professional-facing documents accessed via medicines databases and company websites
- Risk Minimisation Materials (RMMs) — educational materials for patients and HCPs in REMS/risk management programmes
- Patient support programme documents — PDFs distributed through digital patient support services
- Clinical trial participant information sheets — documents provided to trial participants digitally
- Regulatory submission documents — when made accessible to patients or lay audiences
If a patient with a visual impairment or dyslexia cannot independently access a PIL or RMM document using a screen reader, that is an EAA violation.
The regulatory format conflict
Pharmaceutical documents face a constraint that most other EAA-covered sectors do not: the European Medicines Agency (EMA) specifies mandatory QRD (Quality Review of Documents) templates for PILs and SmPCs. These templates define font, layout, structure, and content requirements.
PDFs created to QRD templates typically use multi-column layouts, specific typography, and fixed visual formatting. These characteristics make WCAG 1.4.10 Reflow compliance impossible while keeping the document as a PDF.
The EMA has issued guidance acknowledging the tension between QRD template requirements and accessibility, recommending that companies provide accessible alternative formats alongside the required PDF format.
What EAA requires for pharmaceutical documents
EAA references EN 301 549, which in turn references WCAG 2.1 Level AA. For pharmaceutical PDFs distributed digitally, the critical requirements are:
| WCAG Criterion | Common PDF failure |
|---|---|
| 1.3.1 Info and Relationships | QRD-template PDFs often lack proper heading tags |
| 1.4.3 Contrast Minimum | Box text and side panels frequently fail contrast |
| 1.4.10 Reflow | Multi-column PIL layout cannot reflow to 320px |
| 3.1.1 Language of Page | Language metadata often missing in exported PDFs |
| 4.1.2 Name, Role, Value | Interactive form fields in digital PILs need labels |
Compliance approach for pharmaceutical companies
Short-term: Dual-format distribution
The most pragmatic immediate approach is to provide two versions of each document:
- QRD-compliant PDF — maintains regulatory format requirements
- Accessible EPUB3 — satisfies EAA/WCAG 2.1 AA including Reflow
This approach is explicitly recommended by EMA guidance on digital PIL accessibility. The accessible format does not need to match the QRD visual template — it needs to contain the same content with correct accessibility structure.
PIL-to-EPUB3 conversion workflow
- Upload each PIL PDF to toolkit.bot/pdf2epub
- Receive accessible EPUB3 in under 30 seconds
- Run ACE by DAISY validation:
npm install -g @daisy/ace && ace pil.epub -o report - Add alt text for any chemical structure diagrams or figures missing descriptions
- Publish EPUB3 alongside PDF on your product page or digital PIL system
For large portfolios
Pharmaceutical companies with large medicine portfolios can automate PIL-to-EPUB3 conversion via the toolkit.bot API. The API accepts PDF uploads and returns accessible EPUB3 files with EPUB Accessibility 1.1 metadata — suitable for integration into document management systems or digital PIL platforms.
API pricing starts at EUR 29/month for bulk workflows. See pricing.
Priority documents to convert
- PILs for high-volume medicines — highest patient impact, highest compliance risk
- RMMs for high-risk medicines — regulatory significance of accessibility in risk communications
- Patient support programme materials — directly used by patients, no regulatory format constraint
- SmPCs — professional-facing but still EAA-covered when distributed digitally
Convert PILs and pharmaceutical PDFs to accessible EPUB3. Free tier: 5 conversions/month, no account required.
Try free → API: EUR 29/month